Varilrix

What is it?

A preparation of live attenuated virus available as a powder with solvent for reconstitution and injection comprising 1033 plaque-forming units of varicella-zoster (Oka strain) per 0.5ml.

Medical Uses

Immunisation of healthy adolescents and adults who have been discovered to be seronegative to varicella zoster.

Dosage

Adults, 0.5ml by subcutaneous injection followed by second dose after 2 months, (minimum dose interval is 6 weeks). Children who are at risk due to close contact with persons at high risk of infection, aged 1 to 12 years, 1x0.5ml as single dose.

Special Care

Signs of skin rash, severe skin disorders. patients should be advised to avoid contact with persons who are at high risk of infection. Women of child-bearing age must use effective contraception during course of immunisation and for 3 months afterwards.

Avoid Use

Infants aged under 12 months, pregnancy, breastfeeding, immunodeficiency, whether primary or acquired.

Possible Drug and Food Interactions

Salicylates - duringcourse of immunisation and for following 6 weeks; course must not be given within 3 months of receiving immunoglobulins or blood transfusion.

Known Side Effects

Reaction at injection site, headache, fever, rash, fatigue. Any adverse side effects must be reported to the Committee on the Safety of Medicines (CSM).